AvalonBay Communities, Inc. (AVB) Analysts See $2.25 EPS; Insmed (INSM) Had 8 Bullish Analysts

January 14, 2018 - By Dolores Ford

Analysts expect AvalonBay Communities, Inc. (NYSE:AVB) to report $2.25 EPS on February, 7.They anticipate $0.13 EPS change or 6.13% from last quarter’s $2.12 EPS. AVB’s profit would be $310.72M giving it 18.69 P/E if the $2.25 EPS is correct. After having $2.19 EPS previously, AvalonBay Communities, Inc.’s analysts see 2.74% EPS growth. The stock decreased 0.91% or $1.54 during the last trading session, reaching $168.23. About 494,377 shares traded. AvalonBay Communities, Inc. (NYSE:AVB) has risen 6.66% since January 14, 2017 and is uptrending. It has underperformed by 10.04% the S&P500.

Among 10 analysts covering Insmed (NASDAQ:INSM), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Insmed had 25 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Buy” rating by Evercore given on Wednesday, August 16. The company was maintained on Monday, November 6 by H.C. Wainwright. The firm has “Buy” rating given on Friday, September 4 by Zacks. The stock of Insmed Incorporated (NASDAQ:INSM) earned “Buy” rating by Stifel Nicolaus on Thursday, January 4. The stock of Insmed Incorporated (NASDAQ:INSM) has “Neutral” rating given on Monday, November 9 by UBS. Citigroup maintained Insmed Incorporated (NASDAQ:INSM) rating on Wednesday, March 16. Citigroup has “Neutral” rating and $13 target. Cowen & Co maintained Insmed Incorporated (NASDAQ:INSM) on Thursday, July 20 with “Buy” rating. The company was maintained on Thursday, July 20 by H.C. Wainwright. As per Wednesday, September 6, the company rating was maintained by H.C. Wainwright. The company was downgraded on Monday, August 10 by Zacks. See Insmed Incorporated (NASDAQ:INSM) latest ratings:

04/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $43.0 Upgrade
04/01/2018 Broker: Robert W. Baird Rating: Buy New Target: $42.0 Maintain
04/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $35.0 Maintain
06/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $35.0 Maintain
02/11/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $43.0 Maintain
30/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $32.0 Maintain
11/09/2017 Broker: Cowen & Co Rating: Buy New Target: $54.0 Maintain
06/09/2017 Broker: Robert W. Baird Rating: Buy New Target: $32.0 Maintain
06/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $35.0 Maintain
05/09/2017 Broker: Leerink Swann Rating: Buy Maintain

Investors sentiment increased to 1.27 in Q3 2017. Its up 0.41, from 0.86 in 2017Q2. It increased, as 27 investors sold AvalonBay Communities, Inc. shares while 128 reduced holdings. 58 funds opened positions while 139 raised stakes. 128.20 million shares or 3.63% less from 133.03 million shares in 2017Q2 were reported. Kennedy Cap Mngmt Incorporated reported 0.07% stake. Moreover, Liberty Mutual Grp Asset Mgmt has 0.06% invested in AvalonBay Communities, Inc. (NYSE:AVB) for 5,999 shares. Sii Investments Wi holds 0.01% or 1,372 shares. Cadence Cap Mgmt Limited Liability Corporation has 11,251 shares. Quantitative Systematic Strategies Limited Liability Corp has 0.12% invested in AvalonBay Communities, Inc. (NYSE:AVB) for 2,482 shares. 433 are owned by Cornerstone Advsrs. Conning Inc accumulated 4,179 shares. Fjarde Ap has 0.11% invested in AvalonBay Communities, Inc. (NYSE:AVB). Ar Asset Management stated it has 5,000 shares or 0.35% of all its holdings. Natixis invested in 10,476 shares or 0.02% of the stock. Blackrock reported 14.93 million shares. California State Teachers Retirement Sys, California-based fund reported 240,343 shares. Department Mb Finance Bancorporation N A has 27 shares for 0% of their portfolio. Retail Bank Of New York Mellon Corporation owns 3.18 million shares. 11,789 are owned by Qs Limited Liability Company.

AvalonBay Communities, Inc. engages in the development, redevelopment, acquisition, ownership, and operation of multifamily communities in the United States. The company has market cap of $23.23 billion. As of January 31, 2009, the firm owned or held a direct or indirect ownership interest in 164 operating apartment communities comprising 45,728 apartment homes in 10 states and the District of Columbia. It has a 26.31 P/E ratio. It also held a direct or indirect ownership interest in 14 communities under construction, as well as held rights to develop an additional 27 communities.

Among 25 analysts covering Avalonbay Communities Inc. (NYSE:AVB), 12 have Buy rating, 1 Sell and 12 Hold. Therefore 48% are positive. Avalonbay Communities Inc. had 70 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was upgraded by Evercore to “Outperform” on Monday, September 25. BMO Capital Markets maintained it with “Hold” rating and $19100 target in Wednesday, August 2 report. The firm has “Buy” rating by Evercore given on Monday, November 28. As per Tuesday, August 8, the company rating was maintained by RBC Capital Markets. Evercore maintained the stock with “Buy” rating in Tuesday, September 8 report. The rating was upgraded by Robert W. Baird on Friday, December 11 to “Outperform”. The firm has “Buy” rating given on Friday, November 10 by Robert W. Baird. On Monday, November 27 the stock rating was maintained by BMO Capital Markets with “Hold”. The company was maintained on Monday, July 3 by Jefferies. The firm has “Buy” rating given on Wednesday, August 10 by Deutsche Bank.

Since December 11, 2017, it had 0 buys, and 3 insider sales for $5.26 million activity. NAUGHTON TIMOTHY J sold 25,160 shares worth $4.63 million. 1,500 shares were sold by Breslin Sean J., worth $273,975. HOREY LEO S III also sold $365,500 worth of AvalonBay Communities, Inc. (NYSE:AVB) shares.

The stock increased 1.28% or $0.4 during the last trading session, reaching $31.66. About 812,194 shares traded or 22.10% up from the average. Insmed Incorporated (NASDAQ:INSM) has risen 57.88% since January 14, 2017 and is uptrending. It has outperformed by 41.18% the S&P500.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company has market cap of $2.43 billion. The companyÂ’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It currently has negative earnings. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension.

Since September 5, 2017, it had 0 insider buys, and 2 selling transactions for $2.70 million activity. SHAROKY MELVIN MD sold 50,000 shares worth $1.37 million. HAYDEN DONALD J JR had sold 45,000 shares worth $1.34M.

Investors sentiment increased to 3.74 in Q3 2017. Its up 1.98, from 1.76 in 2017Q2. It improved, as 11 investors sold Insmed Incorporated shares while 16 reduced holdings. 44 funds opened positions while 57 raised stakes. 144.25 million shares or 160.06% more from 55.47 million shares in 2017Q2 were reported. California-based Ecor1 Limited Liability Co has invested 1.69% in Insmed Incorporated (NASDAQ:INSM). Nationwide Fund Advisors, Pennsylvania-based fund reported 41,302 shares. Point72 Asset Limited Partnership stated it has 0.02% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Quantbot Techs Limited Partnership owns 2,722 shares. Senzar Asset Limited Com has invested 1.82% in Insmed Incorporated (NASDAQ:INSM). Goldman Sachs Group Incorporated stated it has 361,328 shares or 0% of all its holdings. Principal Fincl Grp Inc reported 202,131 shares or 0.01% of all its holdings. Amalgamated Bank owns 9,431 shares or 0.01% of their US portfolio. Intll Group invested in 49,284 shares. Campbell & Invest Adviser Limited Liability reported 8,194 shares or 0.21% of all its holdings. Moreover, Ra Capital Management Limited has 2.04% invested in Insmed Incorporated (NASDAQ:INSM) for 722,714 shares. J Goldman And Lp reported 0.14% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Metropolitan Life Insurance Ny invested in 0.01% or 48,976 shares. Prudential Finance holds 7,440 shares or 0% of its portfolio. Bnp Paribas Arbitrage reported 8,365 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>